Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Thermi and Sinclair terminate their collaboration on Silhouette Instalift™

Posted on: 22 Feb 18
Thermi and Sinclair terminate their collaboration on Silhouette Instalift™ - Thermi, an Almirall company, and Sinclair, have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift™ in the US. - The decision has been reached by both companies with the aim to focus on their current core business.

PR Newswire

IRVING, Texas, Feb. 22, 2018

IRVING, Texas, Feb. 22, 2018 /PRNewswire/ -- Thermi, an Almirall S.A. (ALM) company and Sinclair Pharma plc (SPH.L), today announced that they have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift™.

The injectable Silhouette Instalift™ and ThermiRF® technologies provide complementary options for physicians as both offer minimally invasive procedures with consistent outcomes. Both companies have been working through a joint marketing agreement for two years. Thermi and Sinclair have decided, given the growth opportunities in this market, to focus on their own core business in order to fully leverage its potential.

Under the terms of the agreement entered into in May 2016, Thermi was granted with exclusive four-year distribution rights for the US market until mid-2020. The agreement involved a material investment in the launch and marketing of Silhouette Instalift™ by Sinclair. Almirall will receive an undisclosed consideration from Sinclair.

Thermi will continue offering the ThermiRF® platform, which enables aesthetic physicians to perform from non to micro-invasive treatment solutions, like ThermiTight®, available in the US as a single treatment for aging neck and other body areas. Thermi is a world leader in minimally invasive thermistor-regulated energy solutions for aesthetics, dermatology and women's health.

About Thermi

Thermi, an Almirall Company, is a leading global manufacturer of temperature controlled radiofrequency technology. The company's flagship product is ThermiRF®, a platform technology that uses temperature as an endpoint for various minimally and non-invasive applications (ThermiTight®, ThermiRase®, ThermiSmooth® Face, ThermiVa®, etc.). Thermi also offers the Thermi250™ device as the newest innovative RF for body. Founded in 2012, Thermi is a US based company with its headquarters in Irving, TX and R&D in Boston, MA. 

For more information, please visit

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed.

The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenues in 2016 were 859.3 million euros and more than 2,000 employees are devoted to Science.

Media contact:

Investors & Corporate Communications contact:

VegaRun PR 


Dawn Maniglia 

Pablo Divasson del Fraile

Senior Vice President

p: 212.453.2064 | c: 917.862.5444               

Tel.: +(34) 93 291 30 87



View original content with multimedia:


PR Newswire

Last updated on: 22/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.